The Bull Rankings scorecard — our quality-growth score is 88.1 / 100, built from three pillars each graded 0–100 against sector peers: Quality 79, Growth 100, Value 87. At today's price, our reverse-DCF read says the market is implicitly betting on an outright decline in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
Oscar Health is a high‑growth, high‑quality health‑tech play that the market is undervaluing. At $27.97 the stock trades at a PE of 21.5 and a PS of 0.6, yet the company is delivering 27.5% FY revenue growth and a 34.3% ROE. Our Bull Rankings model awards OSCR an 88.1/100 quality‑growth score, with Growth at a perfect 100 and Quality the only weak spot at 79. The price‑to‑earnings multiple already reflects a modest premium for growth, but the reverse‑DCF shows the market is assuming a decline in free‑cash‑flow growth over the next decade—an assumption that flies in the face of the current growth trajectory. In short, the stock is priced for disappointment while the fundamentals scream continuation.
What the business actually is
Oscar Health sells health insurance plans to individuals, families, employees and small groups across the United States. Its core revenue comes from premiums on those plans, but the company also monetises the +Oscar platform, a suite of digital tools that power provider‑payor interactions, a Campaign Builder that offers engagement and recommendation services, and a line of reinsurance products. Brokers use Oscar’s enrollment platform to shop, buy and enroll consumers in medical and supplemental health products, creating a sticky distribution channel that feeds both the insurance and technology sides of the business.
Why it can keep compounding
The strongest pillar in our model is Growth, and Oscar’s moat lives in its technology‑enabled member experience. The +Oscar platform integrates telehealth, AI‑driven care navigation and data analytics, delivering lower cost‑to‑serve and higher member satisfaction than legacy insurers. That digital edge translates into profit margins of 3.6%—a respectable figure for a plan‑seller still scaling its tech stack. Coupled with a debt‑to‑equity of 0.23, the balance sheet is light enough to fund continued product investment without diluting shareholders. The high ROE of 34.3% shows the business is turning equity into earnings at a rate that few plan providers can match, reinforcing the durability of its returns. Competitors would need to rebuild a comparable tech ecosystem and broker network from scratch, a hurdle that gives Oscar a defensible advantage for the foreseeable future.
The valuation question
At a PE of 21.5 and PEG of 0.78, the market is already pricing in some growth slowdown. The reverse‑DCF built into our model indicates that the current price implies free‑cash‑flow growth will decline over the next ten years. Yet Oscar is posting 27.5% revenue growth YoY and generating $4.4 b of free cash flow over the trailing twelve months. The implied negative FCF trajectory is therefore at odds with the actual top‑line momentum. The analyst consensus target of $29 and a range of $19–$39 suggest modest upside, but the upside is capped because the valuation already assumes the growth premium is fading. In other words, the market is being overly pessimistic; the price is anchored to a future where growth stalls, while the fundamentals still point to acceleration.
The bear case
Skeptics will point to the beta of 2.38, indicating Oscar’s stock is highly volatile and vulnerable to broader market swings. A dip in the tech‑heavy health‑insurance sector could crush the share price, especially given the 52‑week low of $10.69 still within reach. Moreover, the Quality pillar at 79 is the weakest of the three, hinting that operational execution or risk management could be a concern. If margins were to slip below the current 3.6% or if the free‑cash‑flow generation falters, the reverse‑DCF’s pessimistic growth path would be validated, and the stock could tumble toward its lower historical range.
What would change our mind
A sustained lift in profit margin to double‑digit levels would push the Quality score higher and confirm that the tech moat is translating into pricing power—this would solidify the bullish thesis. Conversely, a breach of the 52‑week low and a slide in ROE below 30% would signal deteriorating returns and could force a re‑rating to “sell.” Finally, if the reverse‑DCF’s implied growth assumption materialises—i.e., free‑cash‑flow growth turns negative for two consecutive quarters—the market’s pessimism would be vindicated and the stock would merit a bearish stance.